ASH 2019 | Fimepinostat with venetoclax in R/R lymphoma
Anas Younes
• 7 Dec 2019
Anas Younes, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, outlines the interesting synergistic anti-tumor effects of fimepinostat (CUDC-907), a dual inhibitor of phosphotidyl-inositol-3-kinases (PI3Ks) and Class I and II histone deacetylases (HDACs), in combination with venetoclax, a BCL2 inhibitor. This novel combination targeting MYC and BCL2 was recently evaluated in a phase 1/2, multi-center, dose-finding trial (NCT01742988), in patients with relapsed/refractory (R/R) lymphoma, R/R diffuse large B-cell lymphoma (DLBCL), or high-grade B-cell lymphoma (HGBL) with or without MYC and BCL2 alterations. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
